Invizyne Technologies (IZTC) Competitors $10.07 -0.03 (-0.25%) As of 08/1/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock IZTC vs. DSGN, ESPR, ELDN, TKNO, BTMD, MDWD, LRMR, TVGN, NLTX, and VTYXShould you be buying Invizyne Technologies stock or one of its competitors? The main competitors of Invizyne Technologies include Design Therapeutics (DSGN), Esperion Therapeutics (ESPR), Eledon Pharmaceuticals (ELDN), Alpha Teknova (TKNO), biote (BTMD), MediWound (MDWD), Larimar Therapeutics (LRMR), Semper Paratus Acquisition (TVGN), Neoleukin Therapeutics (NLTX), and Ventyx Biosciences (VTYX). These companies are all part of the "pharmaceutical products" industry. Invizyne Technologies vs. Its Competitors Design Therapeutics Esperion Therapeutics Eledon Pharmaceuticals Alpha Teknova biote MediWound Larimar Therapeutics Semper Paratus Acquisition Neoleukin Therapeutics Ventyx Biosciences Design Therapeutics (NASDAQ:DSGN) and Invizyne Technologies (NASDAQ:IZTC) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, institutional ownership, risk, media sentiment, dividends, analyst recommendations and profitability. Do analysts prefer DSGN or IZTC? Design Therapeutics presently has a consensus price target of $4.00, suggesting a potential upside of 4.71%. Given Design Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Design Therapeutics is more favorable than Invizyne Technologies.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Design Therapeutics 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Invizyne Technologies 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Is DSGN or IZTC more profitable? Invizyne Technologies' return on equity of 0.00% beat Design Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Design TherapeuticsN/A -22.85% -22.02% Invizyne Technologies N/A N/A N/A Does the media favor DSGN or IZTC? In the previous week, Design Therapeutics had 1 more articles in the media than Invizyne Technologies. MarketBeat recorded 1 mentions for Design Therapeutics and 0 mentions for Invizyne Technologies. Invizyne Technologies' average media sentiment score of 1.11 beat Design Therapeutics' score of 0.00 indicating that Invizyne Technologies is being referred to more favorably in the news media. Company Overall Sentiment Design Therapeutics Neutral Invizyne Technologies Positive Which has preferable valuation and earnings, DSGN or IZTC? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDesign TherapeuticsN/AN/A-$49.59M-$0.99-3.86Invizyne TechnologiesN/AN/AN/AN/AN/A Do insiders & institutionals believe in DSGN or IZTC? 56.6% of Design Therapeutics shares are held by institutional investors. 31.2% of Design Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. SummaryDesign Therapeutics beats Invizyne Technologies on 5 of the 8 factors compared between the two stocks. Get Invizyne Technologies News Delivered to You Automatically Sign up to receive the latest news and ratings for IZTC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IZTC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IZTC vs. The Competition Export to ExcelMetricInvizyne TechnologiesBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$62.99M$267.92M$5.49B$9.52BDividend YieldN/AN/A4.73%4.09%P/E RatioN/AN/A28.7823.81Price / SalesN/A327.48372.2066.04Price / CashN/A22.4435.4557.96Price / BookN/A10.418.275.54Net IncomeN/A-$106.40M$3.25B$259.28M7 Day Performance0.95%-7.85%-3.70%-4.64%1 Month Performance3.33%18.32%4.34%4.41%1 Year PerformanceN/A6.03%25.90%17.95% Invizyne Technologies Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IZTCInvizyne TechnologiesN/A$10.08-0.2%N/AN/A$62.99MN/A0.0029Positive NewsGap UpDSGNDesign Therapeutics0.3422 of 5 stars$4.25+4.9%$4.00-5.9%-24.4%$229.91MN/A-4.2940Upcoming EarningsESPREsperion Therapeutics4.0329 of 5 stars$1.22+6.1%$7.00+473.8%-35.8%$227.93M$332.31M-1.52200News CoverageUpcoming EarningsAnalyst RevisionGap DownELDNEledon Pharmaceuticals2.1629 of 5 stars$3.71+0.5%$9.00+142.6%+17.0%$220.96MN/A-1.7710TKNOAlpha Teknova2.2067 of 5 stars$4.42+7.5%$10.00+126.2%+19.4%$219.64M$37.74M-9.21240BTMDbiote2.9666 of 5 stars$4.12+2.7%$8.00+94.2%-48.0%$219.39M$197.19M6.75194News CoverageUpcoming EarningsMDWDMediWound1.9355 of 5 stars$20.49+2.1%$32.25+57.4%+6.1%$216.91M$20.22M-9.8080LRMRLarimar Therapeutics2.2631 of 5 stars$3.38+3.7%$18.50+447.3%-58.7%$216.42MN/A-2.2730Positive NewsUpcoming EarningsTVGNSemper Paratus Acquisition3.4963 of 5 stars$1.11-3.5%$10.00+800.9%+61.5%$211.48MN/A0.003News CoverageUpcoming EarningsShort Interest ↑NLTXNeoleukin TherapeuticsN/A$22.34-1.2%N/A-46.3%$209.95MN/A-7.1890High Trading VolumeVTYXVentyx Biosciences2.9124 of 5 stars$3.02+2.4%$10.00+231.1%+17.4%$209.93MN/A-1.7330News CoverageShort Interest ↑ Related Companies and Tools Related Companies Design Therapeutics Alternatives Esperion Therapeutics Alternatives Eledon Pharmaceuticals Alternatives Alpha Teknova Alternatives biote Alternatives MediWound Alternatives Larimar Therapeutics Alternatives Semper Paratus Acquisition Alternatives Neoleukin Therapeutics Alternatives Ventyx Biosciences Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IZTC) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersChina just unlocked Nvidia’s AI chips—what that means for youTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredDigital Dollar Alert: Protect Your Wealth Before It’s Too Late134 countries are developing Central Bank Digital Currencies — and the U.S. is quietly testing one. Experts...American Alternative | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Invizyne Technologies Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Invizyne Technologies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free IZTC Stock Alerts